AV Daclatasvir

Ossip Groth (Diskussion | Beiträge)
(Die Seite wurde neu angelegt: „{{up|PHA antivirals by mechanism}} {{tp|p=32812025|t=2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospital…“)
Zum nächsten Versionsunterschied →

---

Version vom 11. April 2021, 16:18 Uhr

PHA antivirals by mechanism

32812025 2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
32812039 2020. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
32812051 2020. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
33063117 2020. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.